The first trial phase of the vaccine, developed to prevent the three most common forms of the virus, was launched under the supervision of the Vaccine Research Centre (VRC).
The vaccine includes
four different modified HIV genes, drawn from the HIV subtypes A and C - the
most common types of HIV in
These three types of HIV account for about 90% of infections worldwide.Health24: Full story